Similar articles

• Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).

  Nienaber CA, Akin I, Schneider S, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Kuck KH; DES.DE Study Group. Nienaber CA, et al. Am J Cardiol. 2009 Nov 15;104(10):1362-9. doi: 10.1016/j.amjcard.2009.06.058. Epub 2009 Sep 26. Am J Cardiol. 2009. PMID: 19892051
• Two-year outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry).

  Roy P, Bonello L, de Labriolle A, Okabe T, Pinto Slottow TL, Steinberg DH, Torguson R, Smith K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R. Roy P, et al. Am J Cardiol. 2008 Aug 1;102(3):292-7. doi: 10.1016/j.amjcard.2008.03.053. Epub 2008 May 28. Am J Cardiol. 2008. PMID: 18638589
• 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).

  Kaltoft A, Jensen LO, Maeng M, Tilsted HH, Thayssen P, Bøttcher M, Lassen JF, Krusell LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Sørensen HT, Thuesen L. Kaltoft A, et al. J Am Coll Cardiol. 2009 Feb 24;53(8):658-64. doi: 10.1016/j.jacc.2008.09.058. J Am Coll Cardiol. 2009. PMID: 19232897
• The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials.

  Kumbhani DJ, Bavry AA, Kamdar AR, Helton TJ, Bhatt DL. Kumbhani DJ, et al. Am Heart J. 2008 Apr;155(4):640-7. doi: 10.1016/j.ahj.2007.11.017. Epub 2008 Feb 21. Am Heart J. 2008. PMID: 18371470 Review.
• [Paclitaxel-eluting stents in treatment of stenoses and chronic occlusions of coronary arteries].

  Maslov LN, Krylov AL. Maslov LN, et al. Angiol Sosud Khir. 2007;13(3):53-60. Angiol Sosud Khir. 2007. PMID: 18382394 Review. Russian.